MTBP and neoplasm: As shown in Figure 5 and Table 2, the overexpression of MTBP in MHCC97-L cells accelerated the elimination of sorafenib in HCC cells and the subcutaneous tumor tissues, and the half-life time (t1/2 values) of sorafenib in HCC cells or tumor tissues was significantly reduced.